Guidant, J&J's Cordis Settle Patent Dispute Over Drug-Coated Stents

Law360, New York (February 24, 2004, 12:00 AM EST) -- Guidant Corp. has acted to decisively settle the medical device maker’s legal challenges in the lucrative market for drug-coated stents, penning yet another settlement agreement with a major competitor.

Guidant and Johnson & Johnson’s Cordis unit agreed to agree settle all outstanding litigation over patents for drug-coated stents and co-promote Cordis’ Cypher Sirolimus-eluting coronary stent, the companies said.

Last year, Guidant was forced to make a $425 million to Cordis after a court ruled that Guidant's Multi-Link Duet Coronary Stent System infringed on the so-called Palmaz...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.